

Syed A. Rizvi, M.D
 Professor of Clinical Neurosciences
 Alpert Medical School of Brown University
 Director Neurology Outpatient Center
 Director MS Center of RI

EDUCATION

Undergraduate	D.J Science College, Karachi, Pakistan	1982-1984
Medical School	Dow Medical College Karachi, Pakistan	1985-1991
	<i>Distinction in Pharmacology</i> <i>Wyeth Gold Medal in Surgery</i> <i>Certificate of Honor</i>	

POSTGRADUATE TRAINING

Medical Internship:	Atlantic City Medical Center Atlantic City, NJ	1992-93
Residency:	Combined Internal Medicine and Neurology Stony Brook University Hospital Stony Brook, NY	1993-97
Chief Resident:	Internal Medicine Stony Brook University Hospital Stony Brook, NY	1997-98
Fellowship:	Neuroimmunology/Multiple Sclerosis Stony Brook, NY	1998-99
EMHL	Executive Master's in Health Care Leadership Brown University	2015-17

PROFESSIONAL LICENCES AND BOARD CERTIFICATION

American Board Psychiatry and Neurology	1999, 2009, 2019
American Board of Internal Medicine	1997
Medical License: State of Rhode Island #10697	2001

ACADEMIC APPOINTMENTS

Assistant Instructor in Neurology, Stony Brook Univ. Hospital, NY	1993-97
Assistant Professor in Neurology, Stony Brook Univ. Hospital, NY	2000-02
Clinical Assistant Professor of Neurology, Alpert Medical School	2002-09
Clinical Associate Professor of Neurology, Alpert Medical School	2009-22
Clinical Professor of Neurology, Alpert Medical School	2022-

HOSPITAL APPOINTMENTS

Attending Neurologist, Rhode Island Hospital, Providence, RI
Consulting Neurologist, Women and Infants Hospital, Providence, RI
Consulting Neurologist, Newport Hospital, Newport, RI
Consulting Neurologist, Meriam Hospital, Providence, RI

OTHER APPOINTMENTS

Chairman, Clinical Advisory Committee, Multiple Sclerosis Society, RI Chapter	2002-2015
Research Advocate, National Multiple Sclerosis Society	2002-
Member, Board of Trustees, Multiple Sclerosis Society	2002-
Director, MS Center of RI	2004-
Infection Control Committee, RIH	2006-2008
P and T committee	2010
Treasurer, Brown Neurology	2012-curr
Director, Neurology Outpatient Center	2015-curr
Director, MS Fellowship	2015-curr
BPI Operational Committee	2019-curr
Lab Stewardship Committee	2021-curr
Medical Specialty Policy Advisory Committee for Neurology (Tuft's)	2019-cur
Independent Peer review consultant Lincoln Financial Group	3/1/2023-11/24/2024

MEMBERSHIP IN SOCIETIES

American Academy of Neurology
National Multiple Sclerosis Society
Rhode Island Medical Society
RI Neurological society

ORIGINAL PUBLICATIONS IN PEER REVIEWED JOURNALS

Krupp LB, **Rizvi SA**, “Symptomatic therapy for under-recognized manifestations of multiple sclerosis.” *Neurology* 2002;58: S32-S39.

Malik K, **Rizvi S**, Vaillancourt PD, “The SUNCT Syndrome: Successfully Treated with Lamotrigine.” *Pain Med* 2002, Jun;3(2):167-8.

Rizvi SA, Bashir K, Khurram, “Other therapy options and future strategies for treating patients with multiple sclerosis.” *Neurology* 2004;63: S47-54.

Cohen BA, Khan O, Jeffery DR, Bashir K, **Rizvi SA**, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H, “Identifying and treating patients with suboptimal responses.” *Neurology* 2004;63: S33-40.

Rizvi SA, Zwibel H, Fox EJ, “Mitoxantrone for multiple sclerosis in clinical practice.” *Neurology* 2004;63: S25-27.

Rizvi SA, Agius MA, “Current approved options for treating patients with multiple sclerosis,” *Neurology* 2004;63: S8-14.

Mellion M, **Rizvi SA**, “Spontaneous bilateral carotid artery dissection and posterior reversible encephalopathy syndrome.” *Neurology*, Dec 2005;65:1990.

Rizvi SA, Kim E, Moodie J, Glatiramer in the treatment of Multiple sclerosis. *International Journal of Nanomedicine* 2006: 1 (3)

RIZVI SA, “Multiple Sclerosis: Current and Future Treatment Options" *Endocrine, Metabolic & Immune Disorders-Drug Targets*” Volume 7, Issue 4, December, 2007

Rizvi S, Diamond A “Neurological complications of Lyme disease” *Med Health R I.* 2008 Jul; 91 (7): 216-8

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. *Neurology.* 2009 Nov 3;73(18):1493-500. (investigator)

Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, He D, Benedict RH, Goodman A, **Rizvi S**, Schwid SR, Weinstock-Guttman B, Westervelt HJ, Wishart H. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. *Neurology* 2011 Apr 26;76(17):1500-7.

Rizvi S Monoclonal Antibodies: An introduction. *Medicine Health Rhode Island* 2011 November: 94(11): 316

Karl Miesel and **Syed A. Rizvi**. Complications of monoclonal antibody therapy. *Medicine Health Rhode Island.* 2011 November 94(11): 317

Valarie Gendron and **Syed A. Rizvi** Role of monoclonal antibodies in Neurological disorders. *Medicine Health Rhode Island* 2011 November: 94(11): 333

G. Cochrane, **S. Rizvi**, A. Abrantes, B. Crabtree, J. Cahill and J. Friedman. Association between fatigue and apathy in patients with either Parkinsons disease or Multiple sclerosis. Parkinsonism and related disorders. Published online July 13, 2015

Cochrane GD, **Rizvi S**, Abrantes A, Crabtree B, Cahill J, Friedman JH. Internal tremors in Parkinson's disease, Multiple Sclerosis and essential tremors. Parkinsonism Relat Disord. 2015 Oct;21(10):1145-7: 10.1016/j.parkreldis.2015.07.014. Epub 2015 Jul 18

Wong B, Cahill J, **Rizvi SA**, "Moving towards a cure for MS: Increased Immunosuppression and striving for NEDA), RI MED J (2018) Mar 1;101(2);26-29

Rizvi, S Neurotherapeutics: Recent developments. RI Medical Journal. 2018 Mar 1;101(2):25

Dakay K, Sarangi S, Kaushal A, **Rizvi S**, Khurshid H, Tung G; Extratemporal FLAIR hyperintensities in anti-Hu paraneoplastic limbic encephalitis. A case report and review of the literature. Open journal of Clinical and Medical Case Reports Volume 4 (2018) Issue 21

Zhang, T, Jambhekar B, Kumar A, **Rizvi S**, Resnik L Shireman T "Assessing the effects of post-acute rehabilitation services on health care outcomes for people with multiple sclerosis" Multiple Sclerosis and Related Disorders Volume 30 May 2019 277-283

Nichola H, Breton R, Ari P and **Rizvi, S** Optic neuritis, encephalitis and leptomeningeal enhancement in a patient with anti-MOG antibodies: a case study Multiple Sclerosis and Related Disorders. Volume 34 September 2019, Pages 14-16

Lupu G, Cahill J, **Rizvi SA**. Vascular malformation masquerading as demyelinating disease. Multiple Sclerosis and related Disorders. Volume 38 February 2020 (online Oct 1, 2019)

Dakay K, Sarangi S, Kaushal A, **Rizvi S**, Khurshid H, Tung G; Extratemporal FLAIR hyperintensities in anti-Hu paraneoplastic limbic encephalitis. A case report and review of the literature. Open journal of Clinical and Medical Case Reports Volume 4 (2018) Issue 21

Bayer AD, Cahill JF, **Rizvi SA**. Multiple Sclerosis relapse presenting as an acute cardiomyopathy. Multiple Sclerosis and Related Disorders. 2019 Jan; 27:7-8. doi: 10.1016/j.msard.2018.09.021. Epub 2018 Sep 19

Baqir H, Cosmo C, Benevenuto D, Morar D, **Rizvi SA**, Batista LM. Ictal Catatonia in Autoimmune Encephalitis. R I Med J (2013). 2020 Apr 1;103(3):55-58. PMID: 32236165; PMCID: PMC8154181.

Nguyen T, McCauley M, Zheng T, **Rizvi SA**. Common Variable Immunodeficiency Presenting as Anti-GAD Cerebellar Ataxia. R I Med J (2013). 2020 Dec 1;103(10):38-39. PMID: 33261233.

Natalie Erlich-Malona, Jonathan Cahill, Saima Chaudhry, Janice Martin, **Syed Rizvi** Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis Multiple Sclerosis and Related Disorders 47 (2021)

Haubrick K, Gadbios E, Campbell S, Young J, Zhang T, **Rizvi S**, Shireman T, Shield R The Lived Experiences of Adults with Multiple Sclerosis. RIMJ (August 2021)

S. Rizvi, T Nguyen, S Chaudhry, K Stavros and N. Ehrlich “Small Fiber Neuropathy in Multiple Sclerosis”: Neuroimmunology Reports dec 2021

Abud AM, **Rizvi S**, Zainah H, O'Brien TC, Villamar MF. Aggressive MOGAD with bilateral corticospinal tract lesions following infection with Jamestown Canyon virus. J Neuroimmunol. 2022 Dec 15;373:577997.

Thayer EL, **Rizvi SA**, Tung GA. Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis. R I Med J (2013). 2024 Jan 4;107(1):26-28. PMID: 38166073

Zurawski, J., Tauhid, S., Healy, B.C., Chu, R., Houtchens, M.K., Jalkh, Y., Khalil, S., Quattrucci, M., Mateen, F.J., Napoli, S., **Rizvi, S.**, Singhal, T. and Bakshi, R. (2025), Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study. J Neuroimaging., 35: e70032.

Albelo-Martínez M, Rizvi S. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics. 2025 May 9

Callen AM, Glanz BI, Tauhid S, Healy BC, Jinich A, Khalil S, Houtchens MK, Mateen FJ, Napoli S, Rizvi S, Singhal T, Zurawski J, Bakshi R. The impact of cladribine tablets on cognition over one year in patients with multiple sclerosis. **Journal of the Neurological Sciences** (submitted)

BOOKS AND BOOK CHAPTERS

Clinical Neuroimmunology: Multiple Sclerosis and related disorders (2011)
Syed A. Rizvi and Patricia K. Coyle (Editors)
Humana Press

Chapters:
Disease Modifying Agents,

Clinical Neuroimmunology: Multiple Sclerosis and related disorders (2019)
Syed A. Rizvi, Jonathan F Cahill and Patricia K. Coyle (Editors) 2nd edition
Humana Press

Chapters:
Disease Modifying agents,
Clinical Decision Making in the Management of MS

GUEST EDITOR

Guest Editor “Monoclonal Antibodies” Journal of Rhode Island Medical Society (Nov 2011)

Guest Editor “Neuro-therapeutics: Recent Development Journal of Rhode Island Medical Society (March 2018))

OTHER NON-PEER REVIEWED PUBLICATIONS

Coyle PK, **Rizvi SA**, “A Global Perspective on Multiple Sclerosis,” Medscape summary, XVII World Congress of Neurology, 2001.

“Use of Neutralizing antibody assays in MS patients,” consensus statement, Boston, September 11, 2003.

CORPORATE AUTHORSHIP (Publications related to research, Local PI)

L B. Krupp, L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler and B. Chandler Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. *Neurology* 2003;60;1923-1930

Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. *Neurology*. Nov 26 2002;59(10):1496-506

L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. *Neurology* 2004 63: 1579-1585

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data *Mult Scler*. 2008 Apr;14(3):370-82. Epub 2008 Jan 21

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS; for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*. 2012 Nov 01. doi: 10.1016/S0140-6736(12)61768-1.

Montalban, X. et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *The New England journal of medicine* 376, 209

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol*. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: *Lancet Neurol*. 2009 Nov;8(11):981. Erratum in: *Lancet Neurol*. 2011 Feb;10(2):115. Erratum in: *Lancet Neurol*. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P]. PMID: 19729344.

REVIEWER

1. Multiple Sclerosis and Related Disorders

ABSTRACTS

Coyle PK, **Rizvi SA**, Melville PM, “Symptomatic Early Lyme Disease in Adults,” *Ann Neurol* 1999;46:488.

Coyle PK, **Rizvi SA**, Bernal O, “Neurologic Involvement in Early Lyme Disease,” *Neurology* 2000(suppl.3);54(7): A157-A158.

Rizvi SA, Robertson S, Krupp LB, Coyle PK, “To Assess the Benefits of Brief Bed Rest on Post Dural-Puncture Headache (PDPH),” *Neurology* 2000;54: A423.

Elkins L, Krupp LB, Smioldo J, **Rizvi SA**, Coyle PK, “Brief Cognitive Screening in Multiple Sclerosis: Mini-mental examination and the Clock Drawing Test,” *AAN*, 2000.

Ravi Y, Hasan M, **Rizvi SA**, Coyle PK, “Neurologic Lyme Disease presenting as Incomplete Transverse Myelitis: Clinical and MRI findings,” *Neurology* 2001;56(suppl3): A479.

Beitinjaneh F, **Rizvi SA**, Coyle PK, Krupp LB, “Diagnostic accuracy of serologic testing for Lyme disease,” *Neurology* 2001;56(suppl 3): A479-A480.

Krupp LB, Christodoulou C, Elkins L, Coyle PK, **Rizvi SA**, “Designing Clinical Trials for Treating MS-Associated Cognitive Impairment,” *Multiple Sclerosis* 2001;412.

Coyle PK, **Rizvi SA** Taylor M, Deng Z, “Acute Lyme disease in Northern America: Neurologic Aspects,” *Neurology* 2002 (suppl 3);58(7): A262.

Rizvi S, Asif M, Crabtree B, “A retrospective analysis of safety and efficacy of mitoxantrone in patients with worsening multiple sclerosis,” for *AAN* 2005.

LB Krupp, C Cristodoulou, A. Goodman, **S Rizvi**, **B Weinstock** “A multicenter randomized clinical trial of Donepezil to treat memory impairment in Multiple Sclerosis”. *Neurology* 2010 (suppl 2) ; 74 (9) A294.

Jayaraman MV, Beland M.D., Atalay M.K., Ahn S.H., DiBisaio E., **Rizvi S.A.** Doppler waveform analysis of jugular venous flow in patients with and without Multiple Sclerosis. *ASNR '11 Scientific Program. 49th Annual meeting, American Society of Neuroradiology, Seattle, WA*

A. Bouley, J. Cahill, A. Daigle, B. Wong. R. Elias, **S. Rizvi**. “Description of patients with benign MS in the treatment era”. Poster *ECTRIMS* 2017, Paris

A. Bouley, J. Cahill, A. Daigle, B. Wong. R. Elias, **S. Rizvi**. Clinical Outcomes in male and female patients with MS in the treatment era. Poster *ECTRIMS* 2017 Paris.

B. Wong, J. Cahill, A. Bouley, A. Daigle, T. Zhang and **S. Rizvi** “Disability progression variability at different ages of diagnosis pf MS. Poster *ECTRIMS* 2017 Paris.

B. Wong, J. Cahill, A. Bouley, A. Daigle, T. Zhang and **S. Rizvi**. Disability and unemployment utilization in patients with MS. PosterECTRIMS 2017 Paris

J. Stone, J. Cahill, **S. Rizvi** “Lack of lymphopenia following first phase of treatment with Alemtuzumab” Poster presentation AAN 2018

N. Haddad, B Roussel, A. Toumi, M. Superdock, A. Mathew, A. pelcovits, **S. Rizvi** “Optic Neuritis, focal encephalitis and leptomeningeal enhancement in a patient with anti-MOG antibodies”. Poster presentation ACP 2019

B. Insley, **S. Rizvi**, J Cahill, J. Stone, C. Eickhoff "Deep Neural Net Forecasting of Multiple Sclerosis Disease Severity" AAN 2019 April 09, 2019; 92 (15 Supplement)

Bellomo M, Abud A, Cahill J, Chaudhry S, Rizvi S. High Efficacy Agents as First Line Treatment of Relapsing Forms of MS. Presented at the Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, April 2022. P16.435.

Erlich-Malona N, Cahill J, Rizvi S. Small Fiber Neuropathy in Multiple Sclerosis: A Case Series. Presented at the Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, April 2022. P3.3099

Abud A, Rizvi S, Stavros K. Diagnosis of Myotonia Congenita and Multiple Sclerosis in a patient with a familial history. Presented at the Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, April 2022. P9. 4-001

Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial. *Neurol Neuroimmunol Neuroinflamm*. 2022 Feb 21;9(3):

Zurawski J, Tauhid S, Healy BC, Houtchens MK, Jalkh Y, Khalil S, Mateen FJ, Napoli SQ, Rizvi SA, Singhal T, Bakshi R - Cladribine therapy is associated with stable cortical gray matter lesion burden in multiple sclerosis: A longitudinal 7T MRI study.

Thayer EL, Rizvi SA, Tung GA. Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis. *R I Med J* (2013). 2024 Jan 4;107(1):26-28. PMID: 38166073.

“A Noteworthy Complication of High Dose Steroids in the Treatment of Transverse Myelitis”, AAN Poster 2024

“A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis”, AAN presentation 2024

“Early-onset Creutzfeldt-Jakob Disease with Prolonged Course and Atypical Features After COVID-19 Illness” AAN Poster 2024

“The impact of cladribine on cognition over one year in patients with multiple sclerosis” AAN 2025

Cladribine is associated with stable cortical gray matter lesion burden in multiple sclerosis: A 7T MRI study Journal of Neuroimaging 2025

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

Treatment of acute Multiple Sclerosis relapses” CME, **Faculty presenter** Post graduate institute of medicine, 2006. MSLeaders.org
<http://www.msleaders.com/modules/conv/ms/0106/transcript.asp>

Management of the breakthrough patients” CME, **Faculty presenter** Post graduate institute of medicine,
2006. MSLeaders.org <http://www.msleaders.com/ms-leaders/cme/mbp.asp>

INVITED PRESENTATIONS (Local)

1996-2000

Medical Malpractice. Neurology Grand Rounds, Stony Brook Hospital

How to get a stroke at a young age. Neurology Grand Rounds, Stony Brook

MRI as living pathology in MS. Neurology Grand Rounds, Stony Brook NY

“Pathogenesis and treatment of Acute Ischemic Stroke,” Neurology Grand Rounds
Stonybrook University Hospital, Stony brook, NY

2001-2005

“CNS Infections,” Neuroscience course lecture, annually, SUNY Stonybrook

“Neuroimmunology,” Neuroscience course lecture, Brown Medical School

“Treatment of Multiple Sclerosis,” Patient Program, Newport Marriot, Newport RI

“Immunology and Treatment of MS,” Grand Rounds, Rhode Island Hospital

“Combination Treatment,” Patient Program, MS society, Cranston Library, RI

“Multiple Sclerosis Update,” Grand Rounds, Roger Williams Hospital,

“Multiple Sclerosis and Cognition,” Grand Rounds, Butler Hospital, Providence RI
 “Headache: case studies,” Noon Conference, Department of Medicine, Rhode Island Hospital
 “Demyelinating Diseases,” Neuroscience course lecture, Brown Medical School
 “Multiple Sclerosis Update,” Grand Rounds, Newport Hospital, Newport RI
 “Combination Treatment,” Patient Program, Newport Hospital, Newport RI
 “Current Issues in MS,” Faculty presentation, Newport RI
 “Case presentation,” Neurology Grand Rounds, Rhode Island Hospital
 “Newly Diagnosed MS,” Patient Program for MS Society, Providence RI
 “Multiple Sclerosis,” Noon conference, Department of Medicine, Rhode Island
 “MS update,” Patient Program for MS Society, Newport Hospital, Newport RI
 “Tume-factive MS” Neurology Grand Rounds, Rhode Island Hospita
 “Tysabri,” Neurology Grand Rounds, Rhode Island Hospital
 “Meningitis,” Department of Medicine Grand Rounds, Rhode Island Hospital
 “Multiple Sclerosis,” Seminar for MS Society, Providence RI
 “Five unusual cases,” Neurology Grand Rounds, Rhode Island Hospital
 “MRI in MS,” Faculty moderator - CME program, Providence, RI
 “Overview of MS,” CME resident seminar, Foxwood Casino, CT

2006-2010

“Genetics in MS,” <u>Program for MS Society</u> , Providence RI	Jan 26, 2006
“Dural AV fistula” <u>Neurology Grand rounds</u> , RIH	Sept 6, 2006
“What every should know about MS” <u>MS society annual meeting Keynote speaker</u> Providence, RI	Oct 19, 2006
“Resident’s guide to MS” <u>CME</u> Mohigan sun, CT,	Oct 28, 2006
“Multiple Sclerosis <u>Grand Round</u> Roger William Hospital	Oct 31, 2006

“Crossfire” MS society, Providence, RI Nov 1, 2006
 “Multiple sclerosis” MS society, Providence RI Jan 13, 2007
 “Treatment Of MS” Faculty CME, Providence RI
 “Future of MS treatment” Grand round Boston University
 Primary Progressive MS” Grand Round presentation RIH
 “MS Jeopardy” MS Society, Providence, RI
 “Overview of MS” (Faculty) MS seminar for residents, CME, Boston Nov 17, 2007
 “CNS complications of Lyme disease” Grand round presentation RIH Feb 27, 2008
 “Newly diagnosed seminar” MS Society, Providence, RI
 “Ask the experts” MS Society, Providence, RI
 “Neurosciences” presentation at Henry Barnard school, RI College
 “MS’ MS Society, Newport, RI
 “MS Jeopardy” MS society, Providence, RI
 “Neurological aspects of terrorism” APPNA meeting, SFO, CA
 “Controversies in MS” MS Cure fund, Burlington Ma,
 ” MRI in MS” Resident conference, NYC
 “Morbidity and Mortality” GR Medicine RIH
 “Multiple Sclerosis Update” Seminar chair CME RIH
 2011-2015
 “Newly diagnosed Seminar” MS Society
 “10 things Primary Care Physician need to know about MS” GR RIH
 “Will the real MS please stand up” Grand Rounds RIH
 “Current treatment options in MS” Pharmacy seminar CME program RI
 “Update on MS” Annual SNERC meeting. RI

“Research in MS” Keynote speaker for NMSS. RI

2016-

“NMDA Encephalitis”. Bench to Bedside. Brown University, Neuroscience	Dec 8, 2016
“MS Update for Eye Docs” resident Conference, Dept. of Ophthalmology.	May 21, 2019
“ High School Outreach Program Speaker” Brown University	July 29, 2021
“Multiple Sclerosis” Bench to Bedside, Brown University, Neuroscience	Oct 14, 2021
“Dr Google” Brown University Med Ed (TED Talk)	Nov 1, 2021
“Building Team Based, Patient Centered MS Care” (PRIME)	Sept. 12 2022
“PML: Bench to bedside” Brown University	April 17 2025

INVITED PRESENTATIONS (National and International)

Novantrone in Clinical Practice, presentation for Serono, Maimi FL	March 6, 2004
Advancing Trends in Multiple Sclerosis, <u>Chair, CME program</u> , Uncasville CT	Jan 31, 2004
Overview of MS,” <u>CME resident seminar</u> , Foxwood Casino, CT	Nov 19, 2005
Update on Multiple Sclerosis <u>International</u> Neurol conf Karachi, Pakistan	Dec 24, 2006
Future of MS Treatment GR Boston University	Sept 4, 2007
Overview of MS, CME seminar Boston	Nov 17, 2007
Neurological aspects of terrorism APPNA meeting, SFO, CA	June 11, 2010
MRI in MS Resident conference, NYC	2010
Will the real MS please standup GR Baystate Med. Springfield, MA	2011
Clinical Decision making in MS GR, Southern Illinois Univ	April 3, 2019
MS update, Landmark Med. Ctr	Feb 14, 2023

GRANTS

Sub-investigator	PI (P. Coyle) Stony Brook	1996-2001
NIH #2R01 AI 31561-04AI		
Chronic Fatigue in Lyme Disease		
Sub-investigator	PI (P. Coyle) Stony Brook	1998-2000
NIH		\$5,300,00
CNS invasion in early B. Burgdorferi infection		
Co-investigator	PI (P. Coyle) Stony Brook	1999-2001
NIH		\$115,000
Neurobehavioral Syndromes of Chronic Lyme Disease		
Local Co-investigator	PI (P. Coyle) Stony Brook	2000-2001
Serono		\$551,000
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial		
Co-investigator	PI (L. Krupp) Stony Brook	2000-2002
NIH		\$485,000
Interventions to improve memory in MS		
Sub-investigator	PI (L. Krupp) Stony Brook	1999-2002
Biogen Idec, Inc. and Cephalon		\$115,000
Use of Avonex to determine Neurobehavioral Correlates of Fatigue		
Local Sub-investigator	PI (P. Coyle) Stony Brook	2000-2001
TEVA		
Phase III placebo-controlled trial of Oral Glatiramer Acetate		
Sub-investigator	PI (P. Coyle) Stony Brook	2000-2002
TEVA		
Promise trial: use of Glatiramer Acetate in Primary Progressive MS		
Sub-investigator	PI (P. Coyle) Stony Brook	1997-2000
SCIREX		\$150,000
Phase II study of Hu23F2G in acute relapsing MS		
Sub-investigator	PI (L. Krupp) Stony Brook	1996-1998
Department of Defense		\$230,000
Evaluation of Desert Storm Syndrome		
PI		2003-2004

Biogen	\$250,00
Avonex and Novantrone combination study	
Study of the safety and efficacy of combination treatment with Avonex and Novantrone in the treatment of multiple sclerosis, project# 5573	
Local PI	2004-2016
Genentech	\$295,000
Phase II/III, Randomized, Double blinded, Placebo controlled Multicenter Study to Evaluate Safety and efficacy of Rituximab in Adults with PPMS, project # 6267	
Local PI	2004-2008
Berlex	\$324,687
BEYOND Study: International, randomized, multicenter, phase III study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks	
Local PI	2003-2006
Berlex	\$198,801
A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-Remitting Multiple Sclerosis Patients Previously Treated with Avonex®	
Protocol 307245B, project# 5556	
Local PI	2003-2006
Biogen	\$105,000
Combination study in RRMS, A multi-center, randomized, blinded, parallel-group study of Avonex® compared with Avonex® in combination with oral methotrexate, intravenous methylprednisolone, or both in subjects with relapsing-remitting multiple sclerosis who have breakthrough disease on Avonex® monotherapy, project # 5736	
Local PI	2005-2008
NIH	\$63,291
Interventions to Improve Memory in Patients with Multiple Sclerosis	
Local PI	2005-2008
TEVA (ASSERT)	\$20,743/pt
A multi-center, randomized, double-blinded, placebo-controlled study assessing add-on effect of oral steroids in relapsing-remitting multiple sclerosis subjects treated with Glatiramer Acetate	
Local PI	2006-2007
Biogen-Idec	\$1559/pt
Antibodies on Interferon Responsive Genes Highlights Biomarker Response (INSIGHT)	
Local PI	2006-2008

TEVA (FORTE)

Double dose Copaxone Study

Local PI

2007-2010

Bio-MS

A Double-Blind, Placebo Controlled Multi-Center Study To Evaluate The Efficacy and Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis” Project# 8455

Local PI

2007-2008

Biogen

Randomized, Multicenter, Double Blinded, Placebo Controlled, dose Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis.”

Local PI

2007-2008

UCB Pharma

Double-Blinded, Placebo-Controlled, Randomized, Parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis to evaluate the safety, tolerability and effects of two doses of CDP323 over 24 weeks with a rater-blinded MRI follow-up over 12 weeks. Project # 8277

Local PI

2007

Biogen

TYGRIS: Tysabri Global Observational Program in Safety

Local PI

2008-2008

Serono

Cladribine in Early MS

Local PI

2008-2016

Genzyme

Phase III Alemtuzumab trial in RRMS” project# 8944

Local PI

2010-2011

Biogen

SURPASS: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β -1a) to Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis

Local PI

2010-2015

Biogen

DECIDE: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex[®] (Interferon β -1a) in Patients with Relapsing-Remitting Multiple Sclerosis

Local PI

2011

Acorda Therapeutics

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis

Local PI 2011-2015
National Institute of Allergy and Infectious Disease (NIAID), through the Immune Tolerance Network (ITN)

A Phase II Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis

Local PI 2011-2013
ABScience

A 96 week, prospective, multicenter, randomized, double- blind, placebo-controlled, 2-parrallel groups, Phase 3 study to compare the efficacy and safety of masitinib 6mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis

Local PI 2011-present
F. HOFFMANN-LA ROCHE Ltd

A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis.

Local PI 2013
Accorda Pharmaceuticals
Phase 1 study of Re-myelinating Monoclonal Antibody

PI 2014-2018
Brown University Bio-bank study
Brown University (Private donor)

Consultant
Effectiveness of Medicaid's home and community Based Services for Persons with MS
PI Theresa Shireman, Brown Public Health 2015

P!
Cervical spinal cord lesions in MS and associated degenerative disc disease.
2015-2016

P!
Cannabis Use in MS Tertiary Care Center. 2015-16

PI 2015
Outcomes of Multiple Sclerosis Patients

P!

Impact of social media in the management of patients with MS	2016
CO-PI	2016
Using machine learning to forecast Multiple Sclerosis (MS) severity score given by the Expanded Disability Status Scale (EDSS)	
PI	
Retro. Analysis of RMS Patients Treated with High Efficacy Agents.	current
PI	
Fatigue in Multiple Sclerosis Patients on High Efficacy Drugs	current

TEACHING ROLES

Stony Brook Medical School, Neuroscience course	1999-2001
Stony Brook Medical Center, Ward and consult attending	1999-2001
Brown Medical School, Neuro-sciences course <i>(yearly)</i>	2002-present
(Lecture and group leader)	
Rhode Island Hospital, Ward and consult attending	2002-present
Teaching attending during resident clinic rotation	2002-present
Morbidity and Mortality Conf. moderator/organizer <i>(monthly)</i>	2010 present
Lecturer, Neuropsychiatry seminar <i>(yearly)</i>	2013-present
Noon Conf. MS lectures to residents and students	2002-present

Awards

Teaching certificate of appreciation and recognition	2010, 2012
Certificate of Exemplary Teaching (BIOL 3652)	2019
Deans award for excellence in teaching	2015, 2017, 2019,2021

Thesis Mentor

Rehabilitation Services Provided to People with Multiple Sclerosis in Nursing Homes

Bianca Jambhekar MPH 2017 Brown university

MS fellowships

2015: Alison Daigle MD	Funded by National MS Society
2016: Elias Roderick MD	Funded by Brown Neurology
2017: Brian Wong MD	Funded by Brown Neurology
2018: Josh Stone MD	Funded by Biogen
2019: Saima Chaudhry	Funded by Biogen
2021 Alex Abud	Funded by Biogen
2022 Mohona Reza	Funded by MS society
2023 Natalia Quinones	Funded by Brown Neurology
2024 Marelisa Albelo	Funded by Brown Neurology
2025 Cameron Stewart	Funded by NMSS

